IBIO, INC. Adjustments to Additional Paid in Capital, Warrant Issued
IBIO, INC. (IBIO) reported Adjustments to Additional Paid in Capital, Warrant Issued of $84.54 million for the 12-month period ending 2026-06-30, per its 10-K filed 2026-08-28.
Financial Statements › Shareholders' Equity › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued · last filed 2026-08-28
- IBIO, INC. adjustments to additional paid in capital, warrant issued for the quarter ending 2026-06-30 was $9.06M.
- IBIO, INC. adjustments to additional paid in capital, warrant issued for the quarter ending 2026-03-31 was $23.54M.
- IBIO, INC. adjustments to additional paid in capital, warrant issued for the quarter ending 2025-12-31 was $5.58M.
- IBIO, INC. adjustments to additional paid in capital, warrant issued for the quarter ending 2025-09-30 was $46.35M.
- IBIO, INC. adjustments to additional paid in capital, warrant issued for fiscal 2026 was $84.54M.
- IBIO, INC. adjustments to additional paid in capital, warrant issued for fiscal 2024 was $3.69M.
- IBIO, INC. adjustments to additional paid in capital, warrant issued for fiscal 2022 was $967.00K.
| Period end | Adjustments to Additional Paid in Capital, Warrant Issued 3 month | Adjustments to Additional Paid in Capital, Warrant Issued 6 month | Adjustments to Additional Paid in Capital, Warrant Issued 9 month | Adjustments to Additional Paid in Capital, Warrant Issued 12 month |
|---|---|---|---|---|
| 2026-06-30 | $9.06M derived: 10-K 12 month − 3 quarters · filed 2026-08-28 | $32.60M derived: sum of 2 quarters · filed 2026-08-28 | $38.19M derived: sum of 3 quarters · filed 2026-08-28 | $84.54M 10-K · filed 2026-08-28 |
| 2026-03-31 | $23.54M 10-Q · filed 2026-05-12 | $29.13M derived: sum of 2 quarters · filed 2026-05-12 | $75.48M derived: sum of 3 quarters · filed 2026-05-12 | |
| 2025-12-31 | $5.58M 10-Q · filed 2026-05-12 | $51.94M derived: sum of 2 quarters · filed 2026-05-12 | ||
| 2025-09-30 | $46.35M 10-Q · filed 2026-05-12 | |||
| 2024-06-30 | $3.69M 10-K · filed 2025-09-05 | |||
| 2022-06-30 | $967.00K 10-K · filed 2023-09-27 | |||
| 2021-12-31 | $967.00K 10-Q/A · filed 2023-05-19 | |||
| 2011-09-30 | -$31.98K 10-Q · filed 2011-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |